Related Experiment Video
Updated: Dec 24, 2025
Experimental Metastasis Assay
Published on: August 24, 2010
Effect of EphA2 knockdown on melanoma metastasis depends on intrinsic ephrinA1 level
Jing Mo1,2, Xiulan Zhao1,2, Xueyi Dong1,2
1Department of Pathology, Tianjin Medical University, 300070, Tianjin, China.
Purpose:
Upregulation of receptor tyrosine kinase EphA2 has been found to be associated with a poor prognosis in many types of cancer and is considered an attractive therapeutic target. As yet, few efforts have been focused on its tumor suppressive activity triggered by its ligand, ephrinA1. Here, we aimed to determine the potential of ephrinA1 as an important player in melanoma metastasis.
Methods:
Data from the Cancer Genome Atlas (TCGA) and the Cancer Cell Line Encyclopedia (CCLE) were analyzed to explore the expression and prognostic implications of EphA2 and ephrinA1 in melanoma. Western blotting, shRNA, colony formation and immunofluorescence assays, as well as two in vivo xenograft models (subcutaneous and metastatic) were used to evaluate the role of EphA2 in melanoma progression. Akt inhibition and ephrinA1-Fc were used to confirm the influence of Akt activation and ephrinA1 levels on the EphA2 effects. Immunohistochemistry (IHC) was performed on xenograft and patient melanoma tissues.
Results:
We found that high levels of ephrinA1, but not EphA2, were negatively correlated with melanoma metastasis. The expression levels of EphA2 and ephrinA1 were not correlated. After EphA2 downregulation, colony forming abilities and lung metastatic growth were reduced in melanoma cell lines with a low ephrinA1 expression, but were increased in melanoma cell lines with a high ephrinA1 expression. EphA2-mediated colony formation in EphA2-high/ephrinA1-low cells was found to be Akt-dependent and to be inhibited by the addition of ephrinA1-Fc. IHC staining of primary melanoma specimens revealed that EphA2-high/ephrinA1-low patients exhibited poorer outcomes than EphA2-high/ephrinA1-high patients.
Conclusions:
From our data we conclude that evaluation of ephrinA1 levels may be helpful for the application of EphA2-targeted therapies and for prognostic predictions in melanoma patients.
Insights
High ephrinA1 levels correlate with reduced melanoma metastasis, suggesting its potential in targeted therapies and prognosis. EphA2 downregulation impacts metastasis differently based on ephrinA1 levels.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Receptor tyrosine kinase EphA2 is often upregulated in cancers, indicating poor prognosis and making it a therapeutic target.
- The tumor-suppressive role of EphA2's ligand, ephrinA1, in melanoma metastasis is largely unexplored.
Purpose of the Study:
- To investigate the role of ephrinA1 in melanoma metastasis.
- To determine the prognostic significance of ephrinA1 and EphA2 in melanoma patients.
Main Methods:
- Analysis of The Cancer Genome Atlas (TCGA) and Cancer Cell Line Encyclopedia (CCLE) data for EphA2 and ephrinA1 expression.
- In vitro assays (Western blotting, shRNA, colony formation, immunofluorescence) and in vivo xenograft models to assess EphA2's role.
- Immunohistochemistry (IHC) on melanoma tissues to correlate protein expression with patient outcomes.
Main Results:
- High ephrinA1 levels, not EphA2, were negatively associated with melanoma metastasis.
- EphA2 downregulation reduced metastasis in low-ephrinA1 cells but increased it in high-ephrinA1 cells.
- EphA2-high/ephrinA1-low melanoma patients showed poorer outcomes compared to EphA2-high/ephrinA1-high patients.
Conclusions:
- EphrinA1 levels are a potential biomarker for predicting melanoma metastasis.
- Assessing ephrinA1 may aid in selecting patients for EphA2-targeted therapies and improving prognostic accuracy.
Related Concept Videos
01:22Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
02:38Mitogens and the Cell Cycle